Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease

Journal of Proteomics

Volumn 72, Issue 6, 2009, Pages 907-917

  Drake, Richard R ^a   White, Krista Y ^a   Fuller, Thomas W ^a   Igwe, Elena ^a   Clements, Mary Ann ^a   Nyalwidhe, Julius O ^a   Given, Robert W ^b   Lance, Raymond S ^a,b   Semmes, O John ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Urology of Virginia   (United States)

Author keywords

Biomarker; Prostate cancer; Prostate specific antigen; Prostatic acid phosphatase; Proximal fluid

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BETA 2 MICROGLOBULIN; GLYCAN; PROSTATE SPECIFIC ANTIGEN; PROSTATIC SECRETORY PROTEIN;

ARTICLE; CANCER INCIDENCE; CANCER SCREENING; DIGITAL RECTAL EXAMINATION; EPITHELIUM CELL; GLEASON SCORE; GLYCOBIOLOGY; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE FLUID; PROSTATE SECRETION; PROSTATECTOMY; PROTEOMICS; SEMINAL VESICLE; TRANSRECTAL ULTRASONOGRAPHY; WESTERN BLOTTING;

BIOLOGICAL MARKERS; BODY FLUIDS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOMICS; HUMANS; MALE; PROSTATE; PROSTATIC DISEASES; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS;

EID: 67651249913     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2009.01.007     Document Type: Article

References (72)

1. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
2. Shibata A., Ma J., and Whittemore A.S. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 90 (1998) 1230-1231
3. Roobol M.J., Zappa M., Maattanen L., and Ciatto S. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 67 (2007) 439-446
4. Sokoll L.J., Wang Y., Feng Z., Kagan J., Partin A.W., Sanda M.G., et al. [- 2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 180 (2008) 539-543
5. Discussion 543.
6. Loeb S., Roehl K.A., Thaxton C.S., and Catalona W.J. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer. Urology 72 (2008) 143-147
7. Thompson I., Thrasher J.B., Aus G., Burnett A.L., Canby-Hagino E.D., Cookson M.S., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007) 2106-2131
8. Lin K., Lipsitz R., Miller T., and Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 149 (2008) 192-199
9. Barry M.J. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344 (2001) 1373-1377
10. Oesterling J.E., Jacobsen S.J., Chute C.G., Guess H.A., Girman C.J., Panser L.A., et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. Jama 270 (1993) 860-864
11. Ross K.S., Carter H.B., Pearson J.D., and Guess H.A. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. Jama 284 (2000) 1399-1405
12. Chodak G.W., Thisted R.A., Gerber G.S., Johansson J.E., Adolfsson J., Jones G.W., et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 330 (1994) 242-248
13. Krahn M.D., Bremner K.E., Asaria J., Alibhai S.M., Nam R., Tomlinson G., et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology 60 (2002) 258-263
14. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
15. Draisma G., Boer R., Otto S.J., van der Cruijsen I.W., Damhuis R.A., Schroder F.H., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
16. Etzioni R., Penson D.F., Legler J.M., di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94 (2002) 981-990
17. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. Jama 293 (2005) 2095-2101
18. Chan D.W., and Sokoll L.J. Prostate-specific antigen: update 1997. J Int Fed Clin Chem 9 (1997) 120-125
19. Gann P.H., Hennekens C.H., and Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. Jama 273 (1995) 289-294
20. Partin A.W., and Oesterling J.E. The clinical usefulness of percent free-PSA. Urology 48 (1996) 1-3
21. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
22. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
23. Thompson I.M., Ankerst D.P., Chi C., Lucia M.S., Goodman P.J., Crowley J.J., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. Jama 294 (2005) 66-70
24. Makarov D.V., and Carter H.B. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol 176 (2006) 2383-2385
25. Wilkinson B.A., and Hamdy F.C. State-of-the-art staging in prostate cancer. BJU Int 87 (2001) 423-430
26. Gutman A.B., and Gutman E.B. An "acid" phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 17 (1938) 473-478
27. Han M., Piantadosi S., Zahurak M.L., Sokoll L.J., Chan D.W., Epstein J.I., et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 57 (2001) 707-711
28. Moul J.W., Connelly R.R., Perahia B., and McLeod D.G. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol 159 (1998) 935-940
29. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., and Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
30. Chang J.J., Shinohara K., Bhargava V., and Presti J.C. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 160 (1998) 2111-2114
31. Reed A., Ankerst D.P., Pollock B.H., Thompson I.M., and Parekh D.J. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. J Urol 178 (2007) 1929-1932
32. Discussion 1932.
33. Thompson I.M., Pauler Ankerst D., Chi C., Goodman P.J., Tangen C.M., Lippman S.M., et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol 25 (2007) 3076-3081
34. Tsai H.K., D'Amico A.V., Sadetsky N., Chen M.H., and Carroll P.R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
35. Braga-Basaria M., Dobs A.S., Muller D.C., Carducci M.A., John M., Egan J., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
36. Malcolm J.B., Derweesh I.H., Kincade M.C., DiBlasio C.J., Lamar K.D., Wake R.W., et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 14 (2007) 3551-3559
37. Lage M.J., Barber B.L., and Markus R.A. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70 (2007) 1104-1108
38. Brillard-Bourdet M., Rehault S., Juliano L., Ferrer M., Moreau T., and Gauthier F. Amidolytic activity of prostatic acid phosphatase on human semenogelins and semenogelin-derived synthetic substrates. Eur J Biochem 269 (2002) 390-395
39. Meares E.M., and Stamey T.A. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 5 (1968) 492-518
40. Nickel J.C., Alexander R.B., Schaeffer A.J., Landis J.R., Knauss J.S., and Propert K.J. Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls. J Urol 170 (2003) 818-822
41. Ludwig M., Schroeder-Printzen I., Ludecke G., and Weidner W. Comparison of expressed prostatic secretions with urine after prostatic massage-a means to diagnose chronic prostatitis/inflammatory chronic pelvic pain syndrome. Urology 55 (2000) 175-177
42. Serkova N.J., Gamito E.J., Jones R.H., O'Donnell C., Brown J.L., Green S., et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 68 (2008) 620-628
43. Marks L.S., Fradet Y., Deras I.L., Blase A., Mathis J., Aubin S.M., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532-535
44. Tinzl M., Marberger M., Horvath S., and Chypre C. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 46 (2004) 182-186
45. Discussion 187.
46. van Gils M.P., Cornel E.B., Hessels D., Peelen W.P., Witjes J.A., Mulders P.F., et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 67 (2007) 881-887
47. van Gils M.P., Hessels D., van Hooij O., Jannink S.A., Peelen W.P., Hanssen S.L., et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13 (2007) 939-943
48. Groskopf J., Aubin S.M., Deras I.L., Blase A., Bodrug S., Clark C., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089-1095
49. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587-1592
50. Hessels D., Smit F.P., Verhaegh G.W., Witjes J.A., Cornel E.B., and Schalken J.A. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 13 (2007) 5103-5108
51. Laxman B., Morris D.S., Yu J., Siddiqui J., Cao J., Mehra R., et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68 (2008) 645-649
52. Mehra R., Han B., Tomlins S.A., Wang L., Menon A., Wasco M.J., et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 67 (2007) 7991-7995
53. Bolduc S., Lacombe L., Naud A., Gregoire M., Fradet Y., and Tremblay R.R. Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J 1 (2007) 377-381
54. Takayama T.K., Vessella R.L., Brawer M.K., True L.D., Noteboom J., and Lange P.H. Urinary prostate specific antigen levels after radical prostatectomy. J Urol 151 (1994) 82-87
55. DeVere White R.W., Meyers F.J., Soares S.E., Miller D.G., and Soriano T.F. Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy. J Urol 147 (1992) 947-951
56. Pannek J., Rittenhouse H.G., Evans C.L., Finlay J.A., Bruzek D.J., Cox J.L., et al. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology 50 (1997) 715-721
57. Malavaud B., Salama G., Miedouge M., Vincent C., Rischmann P., Sarramon J.P., et al. Influence of digital rectal massage on urinary prostate-specific antigen: interest for the detection of local recurrence after radical prostatectomy. Prostate 34 (1998) 23-28
58. Li R., G.Y., Han B.M., Yan X., Utleg A.G., Li W., et al. Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Proteomics Clin App 2 (2008) 543-555
59. Fujita K., Ewing C.M., Sokoll L.J., Elliott D.J., Cunningham M., De Marzo A.M., et al. Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate 68 (2008) 872-882
60. Adachi J., Kumar C., Zhang Y., Olsen J.V., and Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 7 (2006) R80
61. Pilch B., and Mann M. Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol 7 (2006) R40
62. Thompson I.M. Defining high risk prostate cancer-where do we set the bar? A translational science approach to risk stratification. J Urol 176 (2006) S21-S24
63. Discussion S25-S26.
64. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 280 (1998) 969-974
65. Gross M., Top I., Laux I., Kazt J., Curran J., Tindell C., et al. b-2-Microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res 13 (2007) 1979-1986
66. Alexander H., Stegner A.L., Wagner-Mann C., Du Bois G.C., Alexander S., and Sauter E.R. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 10 (2004) 7500-7510
67. Kawinski E., Levine E., and Chadha K. Thiophilic interaction chromatography facilitates detection of various molecular complexes of prostate-specific antigen in biological fluids. Prostate 50 (2002) 145-153
68. Ciucanu I., and Kerek F. A simple and rapid method for the permethylation of carbohydrates. Carbohydr Res 131 (1984) 209-217
69. Lau K.S., and Dennis J.W. N-glycans in cancer progression. Glycobiology 18 (2008) 750-760
70. Jankovic M.M., and Kosanovic M.M. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns. Clin Biochem 38 (2005) 58-65
71. Fukuda M. Cell surface glycoconjugates as onco-differentiation markers in hematopoietic cells. Biochim Biophys Acta 780 (1985) 119-150
72. Ceroni A., Dell A., and Haslam S.M. The GlycanBuilder: a fast, intuitive and flexible software tool for building and displaying glycan structures. Source Code Biol Med 2 (2007) 3